Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Cipher Mining Inc (CIFR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Cipher Mining Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.58 (market cap $5.07B), while Cipher Mining Inc trades at $17.77 (market cap $7.14B). The key difference: Cipher Mining Inc is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Cipher Mining Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | CIFR | |
|---|---|---|
Market Cap | $5.07B | $7.14B |
Sector | Health | Basic Materials |
52-Week High | $29.41 | $29.18 |
52-Week Low | $20.06 | $4.72 |
Enterprise Value | $4.19B | $11.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.
CIFR trades at $18.35, up 12.37% in the last 24 hours, but remains in a bearish technical trend. The company reported a Q2 2026 loss of $0.65 per share, missing estimates, with revenue declining and net losses widening. Despite negative profitability metrics, analyst consensus is unanimously bullish with a $31.78 price target, citing progress in its transition to AI data center operations and accelerated project deliveries.
The outlook hinges on successful execution of its AI infrastructure pivot, offering significant upside if targets are met, but high execution risks and persistent losses pose substantial threats to shareholder value. Investors face volatility amid the business model transition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Cipher Mining Inc
Cipher Mining is an industrial-scale technology company focused on Bitcoin mining infrastructure. It develops and operates data centers in the US designed to strengthen the Bitcoin network and support decentralized finance.
Read more on CIFR →
